{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-004954","form_type":"8-K","ticker":"GNPX","cik":"0001595248","company_name":"Genprex, Inc.","filed_at":"2026-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.583652+00:00","generated_at":"2026-05-16T01:09:30.454861+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Genprex wins Japanese and European patent grants for REQORSA combos; Acclaim-3 update","bullets":["Japanese Patent Office issued favorable Appeal Decision to grant patent for REQORSA + PD-L1 antibodies.","European Patent Office granted patent for REQORSA + PD-1 antibodies to treat cancer.","Acclaim-3 Phase 2 expansion: enrollment of first 25 patients for interim analysis expected by H1 2026; interim analysis in H2 2026.","Phase 2 primary endpoint: 18-week progression-free survival rate; trial targets ~50 patients with ES-SCLC."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-004954","json":"https://secwatch.observer/filing/0001437749-26-004954.json","markdown":"https://secwatch.observer/filing/0001437749-26-004954.md","text":"https://secwatch.observer/filing/0001437749-26-004954.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595248/000143774926004954/0001437749-26-004954-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595248/000143774926004954/gnpx20260220_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T01:09:30.454861+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}